Regeneron Pharmaceuticals Inc. (REGN): Why insiders taking interest in this stock


Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) changes shares on Friday trading session, with a change of 7.80% or $46.57 shares. The trading starts at $602.31 and closed at $597.35 throughout the day. The trading session low price was $598.71 and day high was $646.33 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 2.66 million while its average volume is 1.46M. In other hand, the REGN market cap reached to $73.41B. While, its current target price is $643.92 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 9.44% and up 11.62% for month. Its quarterly performance was 46.86% above, while its half year performance is up 73.40%. REGN yearly performance stood at positive 100.92% and rise 71.49% for year-to-date. Current recommendation for Regeneron Pharmaceuticals Inc. is 2.10.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. REGN EPS (TTM) for 12-month is 19.90. EPS for this year is -10.80%, while for the next year its value is 31.62. Sales growth for the current quarter is 3.85 while its EPS Q/Q reached 35.90%. It has an EPS of 44.00% up for past five years and for the next five years will be up 8.40%.

Let’s take a look on the analyst recommendations on REGN for the current month and previous month. For the current month, 13 of 27 analysts recommend stock as Buy while 0 as Sell, 2 as overweight, 1 as underweight and 11 as Hold. As compared with the previous month ratings, 27 analysts participate in stock recommendation. Out of 27, 0 rated it sell, 13 rated it as Buy and 11 as Hold Ratings. On the other hand, target price ranges from $400.00-$734.00. Average target price for REGN was reached at $604.08.

FMR, LLC, Capital World Investors and Blackrock Inc. are the top three holders in Regeneron Pharmaceuticals Inc. (REGN) stock. On Mar 30, 2020, FMR, LLC has 8.46 million shares which valued 4.13 billion. On Mar 30, 2020, Capital World Investors owned 7.13 million shares which valued at 3.48 billion. On Mar 30, 2020, Blackrock Inc. has a total of 6.6 million shares which valued at 3.22 billion. In the end, Blackrock Inc. have 5.96% shares outstanding of Regeneron Pharmaceuticals Inc. (REGN) on Mar 30, 2020. The insider ownership moved to 1.00% and institutional holding shifted to 69.90%.

The company posted an EPS (TTM) of 19.90. According to the most recent quarter report on (Jun 2020), 18 analysts estimated an average EPS of 6.14, while 6.02 EPS posted a year ago period. Analyst Estimated EPS for REGN published in the report was 4.39-7.38 during the same period. Comparing with last year, the average estimated EPS was 6.02 which is lower than 6.6 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for REGN rise 54.57% for period of 200 days. SMA for 50 days was 13.79% which is showing green signal, while SMA-20 was 8.99%. The moving average value for Regeneron Pharmaceuticals Inc. (REGN) is 467.05 and 580.84 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in REGN stock. On Jun 16, Fenimore Christopher R., VP Controller, sold 3,556 trading shares at the cost of $590.89, which valued at 2.1 million. On Jun 11, Zoghbi Huda Y, Director, sold 1,706 shares at the cost of $625.00, with total shares of 643. On Jun 11, Landry Robert E, EVP Finance CFO, sold 988 shares at the cost of 612.08. After this transaction, Landry Robert E total shares reached to 24,373 which valued at 0.6 million.